Skip to main content
. Author manuscript; available in PMC: 2024 Sep 6.
Published in final edited form as: Pharmacol Res. 2024 Jan 2;200:107055. doi: 10.1016/j.phrs.2023.107055

Fig. 1.

Fig. 1.

Effects of empagliflozin on cognitive and physical impairment. A) Montreal Cognitive Assessment (MoCA) Score at baseline and follow-up in patients treated or not with empagliflozin; B) multivariable regression analysis using the improvement in MoCA score as dependent variable; C) Gait Speed at baseline and follow-up in patients treated or not with empagliflozin; D) multivariable regression analysis using the improvement in GST score as dependent variable. *: 0.05, **: p<0.01; paired samples Wilcoxon test.